Cholesteatoma growth and proliferation: Posttranscriptional regulation by microRNA-21

Otology and Neurotology

Volumn 30, Issue 7, 2009, Pages 998-1005

  Friedland, David R ^a   Eernisse, Rebecca ^a   Erbe, Christy ^a   Gupta, Nidhi ^a   Cioffi, Joseph A ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Cholesteatoma; hsa miR 21; MicroRNA; Programmed cell death 4; PTEN; Signal transducer and activator of transcription 3

Indexed keywords

CD14 ANTIGEN; GLYCOPROTEIN GP 130; INTERLEUKIN 6 RECEPTOR; MICRORNA; MICRORNA 21; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ADULT; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CHOLESTEATOMA; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; TUMOR GROWTH; WESTERN BLOTTING;

ADULT; ANTIGENS, CD14; APOPTOSIS REGULATORY PROTEINS; CELL PROLIFERATION; CHOLESTEATOMA; EAR; HUMANS; MICRORNAS; PTEN PHOSPHOHYDROLASE; RECEPTORS, INTERLEUKIN-6; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA PROCESSING, POST-TRANSCRIPTIONAL; RNA-BINDING PROTEINS; SKIN; STAT3 TRANSCRIPTION FACTOR; UP-REGULATION;

EID: 70349755838     PISSN: 15317129     EISSN: 15374505     Source Type: Journal    
DOI: 10.1097/MAO.0b013e3181b4e91f     Document Type: Article

References (55)

1. Vikram BK, Udayashankar SG, Naseeruddin K, Venkatesha BK, Manjunath D, Savantrewwa IR. Complications in primary and secondary acquired cholesteatoma: a prospective comparative study of 62 ears. Am J Otolaryngol 2008;29:1-6. (Pubitemid 350180152)
2. Friedland DR, Pensak ML, Kveton JF. Cranial and intracranial complications of acute and chronic otitis media. In: Wackym PA, Snow J, eds. Ballenger's Otorhinolaryngology Head and Neck Surgery. Hamilton, Ontario, Canada: BC Decker, 2008. In press.
3. Mukherjee P, Saunders N, Liu R, Fagan P. Long-term outcome of modified radical mastoidectomy. J Laryngol Otol 2004;118:612-616 (Pubitemid 39280055)
4. Yung M, Jacobsen NL, Vowler SL. A 5-year observational study of the outcome in pediatric cholesteatoma surgery. Otol Neurotol 2007;28:1038-1040 (Pubitemid 350191074)
5. Semaan MT, Megerian CA. The pathophysiology of cholesteatoma. Otolaryngol Clin North Am 2006;39:1143-1159
6. Olszewska E, Wagner M, Bernal-Sprekelsen M, et al. Etiopathogenesis of cholesteatoma. Eur Arch Otorhinolaryngol 2004;261:6-24.
7. Kim HJ, Chole RA. Experimental models of aural cholesteatomas in Mongolian gerbils. Ann Otol Rhinol Laryngol 1998;107:129-134
8. Kim CS, Lee CH, Chung JW, Kim CD. Interleukin-1 alpha, interleukin-1 beta and interleukin-8 gene expression in human aural cholesteatomas. Acta Otolaryngol 1996;116:302-306
9. Hwang SJ, Kang HJ, Song JJ, et al. Up-regulation of peroxidase proliferator-activated receptor gamma in cholesteatoma. Laryngoscope 2006;116:58-61. (Pubitemid 44383962)
10. Bujia J, Kim C, Boyle D, Hammer C, Firestein G, Kastenbauer E. Quantitative analysis of interleukin-1-alpha gene expression in middle ear cholesteatoma. Laryngoscope 1996;106:217-220 (Pubitemid 26052782)
11. Ishibashi T, Shinogami M, Kaga K, Fukaya T. Keratinocyte growth factor and receptor mRNA expression in cholesteatoma of the middle ear. Acta Otolaryngol 1997;117:714-718 (Pubitemid 27418201)
12. Kojima H, Matsuhisa A, Shiwa M, et al. Expression of messenger RNA for keratinocyte growth factor in human cholesteatoma. Arch Otolaryngol Head Neck Surg 1996;122:157-160 (Pubitemid 26056773)
13. Song JJ, Chae SW, Woo JS, Lee HM, Jung HH, Hwang SJ. Differential expression of human beta defensin 2 and human beta defensin 3 in human middle ear cholesteatoma. Ann Otol Rhinol Laryngol 2007;116:235-240 (Pubitemid 46452461)
14. Mehta D, Daudia A, Birchall JP, Banerjee AR. The localization of matrix metalloproteinases-8 and -13 in cholesteatoma, deep-meatal and post-auricular skin: a comparative analysis. Acta Otolaryngol 2007;127:138-142 (Pubitemid 46303810)
15. Schmidt M, Grunsfelder P, Hoppe F. Up-regulation of matrix metalloprotease-9 in middle ear cholesteatoma - correlations with growth factor expression in vivo? Eur Arch Otorhinolaryngol 2001;258:472-476
16. Cho JG, Lim HW, Woo JS, Hwang SJ, Lee HM, Chae SW. Overexpression of placenta growth factor in human middle ear cholesteatoma. Acta Otolaryngol 2006;126:900-904
17. Sakamoto T, Kondo K, Yamasoba T, Suzuki M, Sugasawa M, Kaga K. Overexpression of ErbB-2 protein in human middle ear cholesteatomas. Laryngoscope 2004;114:1988-1991 (Pubitemid 39539861)
18. Miyao M, Shinoda H, Takahashi S. Caspase-3, caspase-8, and nuclear factor-kappaB expression in human cholesteatoma. Otol Neurotol 2006;27:8-13. (Pubitemid 43011084)
19. Jeong JH, Park CW, Tae K, et al. Expression of RANKL and OPG in middle ear cholesteatoma tissue. Laryngoscope 2006;116:1180-1184 (Pubitemid 44317947)
20. Huisman MA, De Heer E, Grote JJ. Sustained extracellular signal-regulated kinase1/2 mitogen-activated protein kinase signalling is related to increased p21 expression in cholesteatoma epithelium. Acta Otolaryngol 2005;125:134-140 (Pubitemid 40297906)
21. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-297
22. Fabbri M, Croce CM, Calin GA. MicroRNAs. Cancer J 2008;14:1-6.
23. Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol 2007;302:1-12. (Pubitemid 46096921)
24. Maritano D, Sugrue ML, Tininini S, et al. The STAT3 isoforms alpha and beta have unique and specific functions. Nat Immunol 2004;5:401-409 (Pubitemid 38500089)
25. Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell 2000;100:387-390 (Pubitemid 30818176)
26. Suzuki A, Nakano T, Mak TW, Sasaki T. Portrait of PTEN: messages from mutant mice. Cancer Sci 2008;99:209-213
27. Jansen AP, Camalier CE, Colburn NH. Epidermal expression of the translation inhibitor programmed cell death 4 suppresses tumorigenesis. Cancer Res 2005;65:6034-6041
28. Asangani IA, Rasheed SA, Nikolova DA, et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor PDCD4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008;27:2128-2136
29. Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A, Lund AH. Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem 2008;283:1026-1033
30. Meng F, Henson R, Lang M, et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 2006;130:2113-2129 (Pubitemid 43816961)
31. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007;133:647-658 (Pubitemid 47187346)
32. Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 2005;65:6029-6033 (Pubitemid 40994386)
33. Cioffi JA, Mendolia-Loffredo S, Massey B, Wackym PA. MicroRNA-21 over-expression may contibute to tumor growth in vestibular schwannoma. Abstracts of the Association for Otolaryngology 2008;31:264.
34. Paez JG, Sellers WR. PI3K/PTEN/AKT pathway: a critical mediator of oncogenic signaling. In: Frank DA, ed. Signal Transduction in Cancer. New York: Springer, 2002:145-168
35. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005;24:7455-7464 (Pubitemid 41637985)
36. Hlobilkova A, Knillova J, Bartek J, Lukas J, Kolar Z. The mechanism of action of the tumour suppressor gene PTEN. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2003;147:19-25.
37. Gu J, Tamura M, Pankov R, et al. Shc and FAK differentially regulate cell motility and directionality modulated by PTEN. J Cell Biol 1999;146:389-403. (Pubitemid 29369775)
38. Huisman MA, De Heer E, Grote JJ. Survival signaling and terminal differentiation in cholesteatoma epithelium. Acta Otolaryngol 2007;127:424-429 (Pubitemid 46572874)
39. Yune TY, Byun JY. Expression of PTEN and phosphorylated Akt in human cholesteatoma epithelium. Acta Otolaryngol 2008:1-6.
40. Lu Z, Liu M, Stribinskis V, et al. MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene 2008;27:4373-4379 (Pubitemid 352010003)
41. Sudhoff H, Tos M. Pathogenesis of attic cholesteatoma: clinical and immunohistochemical support for combination of retraction theory and proliferation theory. Am J Otol 2000;21:786-792 (Pubitemid 30812887)
42. Peek FA, Huisman MA, Berckmans RJ, Sturk A, Van Loon J, Grote JJ. Lipopolysaccharide concentration and bone resorption in cholesteatoma. Otol Neurotol 2003;24:709-713 (Pubitemid 37122532)
43. Kato A, Ohashi Y, Masamoto T, Sakamoto H, Uekawa M, Nakai Y. Interleukin-6 and tumour necrosis factor alpha synthesized by cholesteatoma cells affect mucociliary function in the eustachian tube. Acta Otolaryngol Suppl 1998;538:90-97 (Pubitemid 28563329)
44. Wilmoth JG, Schultz GS, Antonelli PJ. Tympanic membrane metalloproteinase inflammatory response. Otolaryngol Head Neck Surg 2003;129:647-654
45. Akimoto R, Pawankar R, Yagi T, Baba S. Acquired and congenital cholesteatoma: determination of tumor necrosis factor-alpha, intercellular adhesion molecule-1, interleukin-1-alpha and lymphocyte functional antigen-1 in the inflammatory process. ORL J Otorhinolaryngol Relat Spec 2000;62:257-265
46. Bujia J, Kim C, Ostos P, Sudhoff H, Kastenbauer E, Hultner L. Interleukin 1 (IL-1) and IL-1-receptor antagonist (IL-1-RA) in middle ear cholesteatoma: an analysis of protein production and biological activity. Eur Arch Otorhinolaryngol 1996;253:252-255 (Pubitemid 26164433)
47. Siddiquee K, Zhang S, Guida WC, et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci U S A 2007;104:7391-7396 (Pubitemid 47185916)
48. Loffler D, Brocke-Heidrich K, Pfeifer G, et al. Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood 2007;110:1330-1333 (Pubitemid 47281433)
49. Lee RJ, Mackenzie IC, Hall BK, Gantz BJ. The nature of the epithelium in acquired cholesteatoma. Clin Otolaryngol Allied Sci 1991;16:168-173
50. Yoshikawa M, Kojima H, Wada K, et al. Identification of specific gene expression profiles in fibroblasts derived from middle ear cholesteatoma. Arch Otolaryngol Head Neck Surg 2006;132:734-742 (Pubitemid 44086435)
51. Laeeq S, Faust R. Modeling the cholesteatoma microenvironment: coculture of HaCaT keratinocytes with WS1 fibroblasts induces MMP-2 activation, invasive phenotype, and proteolysis of the extracellular matrix. Laryngoscope 2007;117:313-318 (Pubitemid 46207894)
52. Elmen J, Lindow M, Schutz S, et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008;452:896-899 (Pubitemid 351550859)
53. Mahadev K, Raval G, Bharadwaj S, et al. Suppression of the transformed phenotype of breast cancer by tropomyosin-1. Exp Cell Res 2002;279:40-51.
54. Raval GN, Bharadwaj S, Levine EA, et al. Loss of expression of tropomyosin-1, a novel class II tumor suppressor that induces anoikis, in primary breast tumors. Oncogene 2003;22:6194-6203 (Pubitemid 37281649)
55. Shah V, Braverman R, Prasad GL. Suppression of neoplastic transformation and regulation of cytoskeleton by tropomyosins. Somat Cell Mol Genet 1998;24:273-280 (Pubitemid 128690204)